GoAI
Get started
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. logo

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

1349.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$2.555

−HK$0.035 · -1.35%

Aug 24, 4:08 PM HKT

1349.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., along with its affiliated entities, is dedicated to the research, development, production, and commercialization of biopharmaceutical products. The company leverages its genetic engineering platform to advance antibody-drug conjugates (ADCs), including CD30-DM1 ADC and Trop2-SN38 ADC, both in Phase I clinical trials for various tumors. Trop2-BB05 ADC is undergoing preclinical evaluation for lung and triple-negative breast cancers, while HER2 ADC has completed preclinical studies for metastatic breast and gastric cancers. Furthermore, Fudan-Zhangjiang utilizes its photodynamic technology platform, featuring hemoporfin in Phase IV clinical trials for port-wine stains, and aminolevulinic acid, which is progressing through Phase II trials for HPV-related cervical conditions and acne, having also finished preclinical investigation for brain gliomas. Its nanotechnology platform is advancing drugs like Nanoparticle Albumin-bound Paclitaxel, undergoing preclinical assessment for oncological applications, and Doxorubicin liposome, also under development for tumors. The firm's expertise in oral solid preparations encompasses obeticholic acid for hepatobiliary and autoimmune disorders; timolol maleate cream, currently in preclinical studies for infantile hemangioma; and the oral formulation FZJ-003, which is in Phase I clinical trials for rheumatoid arthritis and Phase II for atopic dermatitis and ulcerative colitis. Beyond pharmaceuticals, the company is involved in developing both pharmaceutical and medical devices, as well as medical diagnostic solutions and associated services. It also markets everyday consumer goods, clinical laboratory analysis equipment, and relevant software. Additional activities include technology innovation, licensing, consultancy, and promotional efforts, alongside the manufacturing of lyophilized powder injections and active pharmaceutical ingredients (APIs). The company also allocates capital to international medical ventures. Established in 1996, the company operates from its headquarters in Shanghai, People's Republic of China.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Da Jun Zhao
Listed since
Aug 13, 2002
Employees
876

Market position

Day range

Current HK$2.555

52-week range

Current HK$2.555

Open
HK$2.595
Previous close
HK$2.59
Volume
1.14M
0.51× average
Average volume
2.22M
Average daily volume
Market cap
868.7M HKD
Beta
0.09
Market reference 1
50-day average
HK$2.4317
+5.07% above average
200-day average
HK$2.8016
-8.80% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.49B CNY
P/E (TTM)
-69.89×
P/B (TTM)
4.04×
P/S (TTM)
1.44×
EV / EBITDA
-18.25×
Earnings yield
-5.85%
Free cash flow yield
4.20%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.50%
Operating margin
-21.46%
Net margin
-18.90%
Return on equity
-7.24%
Return on assets
-6.41%
Return on invested capital
-7.22%

Financial health

Debt / equity
0.01×
Current ratio
6.05×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends104%58%12%-34%Gross margin, FY2021: 92.90%Gross margin, FY2022: 91.85%Gross margin, FY2023: 91.70%Gross margin, FY2024: 91.37%Gross margin, FY2025: 89.89%Operating margin, FY2021: 19.06%Operating margin, FY2022: 12.92%Operating margin, FY2023: 11.41%Operating margin, FY2024: 0.34%Operating margin, FY2025: -22.66%Net margin, FY2021: 18.71%Net margin, FY2022: 13.38%Net margin, FY2023: 12.77%Net margin, FY2024: 5.60%Net margin, FY2025: -22.36%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 92.90%. Gross margin FY2022 91.85%. Gross margin FY2023 91.70%. Gross margin FY2024 91.37%. Gross margin FY2025 89.89%. Operating margin FY2021 19.06%. Operating margin FY2022 12.92%. Operating margin FY2023 11.41%. Operating margin FY2024 0.34%. Operating margin FY2025 -22.66%. Net margin FY2021 18.71%. Net margin FY2022 13.38%. Net margin FY2023 12.77%. Net margin FY2024 5.60%. Net margin FY2025 -22.36%.

Income trends

Revenue

685.8M CNY-3.33%

Operating income

−155.4M CNY−157.8M CNY

Net income

−153.36M CNY−193.1M CNY
Income trends across reported periods1.27B CNY751.6M CNY233.31M CNY−284.97M CNYRevenue, FY2021: 1.14B CNYRevenue, FY2022: 1.03B CNYRevenue, FY2023: 850.73M CNYRevenue, FY2024: 709.4M CNYRevenue, FY2025: 685.8M CNYOperating income, FY2021: 217.38M CNYOperating income, FY2022: 133.27M CNYOperating income, FY2023: 97.09M CNYOperating income, FY2024: 2.39M CNYOperating income, FY2025: −155.4M CNYNet income, FY2021: 213.3M CNYNet income, FY2022: 138M CNYNet income, FY2023: 108.63M CNYNet income, FY2024: 39.73M CNYNet income, FY2025: −153.36M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.14B CNY. Revenue FY2022 1.03B CNY. Revenue FY2023 850.73M CNY. Revenue FY2024 709.4M CNY. Revenue FY2025 685.8M CNY. Operating income FY2021 217.38M CNY. Operating income FY2022 133.27M CNY. Operating income FY2023 97.09M CNY. Operating income FY2024 2.39M CNY. Operating income FY2025 −155.4M CNY. Net income FY2021 213.3M CNY. Net income FY2022 138M CNY. Net income FY2023 108.63M CNY. Net income FY2024 39.73M CNY. Net income FY2025 −153.36M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue685.8M CNY709.4M CNY850.73M CNY1.03B CNY1.14B CNY
Cost of goods sold69.31M CNY61.21M CNY70.63M CNY84.06M CNY80.96M CNY
Gross profit616.49M CNY648.19M CNY780.11M CNY947.1M CNY1.06B CNY
Research and development357.94M CNY314.16M CNY243.76M CNY226.85M CNY224.39M CNY
Selling, general, and administrative280.17M CNY195.27M CNY271.64M CNY567.58M CNY616.11M CNY
Operating expenses770.37M CNY645.8M CNY683.02M CNY813.83M CNY841.98M CNY
Interest income17.59M CNY5.55M CNY7.97M CNY11.29M CNY5.13M CNY
Interest expense716.34K CNY591.62K CNY3.07M CNY1.54M CNY1.06M CNY
Depreciation and amortization76.62M CNY45.69M CNY59.93M CNY80.97M CNY60.85M CNY
Operating income−155.4M CNY2.39M CNY97.09M CNY133.27M CNY217.38M CNY
Net income−153.36M CNY39.73M CNY108.63M CNY138M CNY213.3M CNY

Company facts updated Aug 24, 2026.

1349.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

ETFs holding 1349.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Dimensional - Emerging Markets Core Equity 2 ETF logoDimensional - Emerging Markets Core Equity 2 ETFDFEM
Market value
42.94K
Weight
0.00%
AUM
9.49B USD
Expense ratio
0.39%
Price / 1D
$39.52-1.03%
Dimensional World ex U.S. Core Equity 2 ETF logoDimensional World ex U.S. Core Equity 2 ETFDFAX
Market value
26.1K
Weight
0.00%
AUM
12.57B USD
Expense ratio
0.28%
Price / 1D
$37.92-0.63%

Continue in GoAI

Research 1349.HK

research.disclaimer